Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 327 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: University of Michigan Rogel Cancer Center Clear all
Withdrawn Phase 2 Interventional

A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma

NCT02649530
View directory record Official record
Conditions
Squamous Cell Carcinoma, Head And Neck
Interventions
WNT974
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine

NCT00156312
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Capecitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The SMART CART Study: Health Information Technology

NCT04051216
View directory record Official record
Conditions
Leukemia, Acute, Leukemia, Lymphoblastic
Interventions
Education information system, Activity monitor, Interview, Survey Administration, Laboratory Biomarker Analysis
Behavioral · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years and older
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 13, 2026, 9:02 PM EDT
Terminated No phase listed Observational

A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer

NCT01409681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

NCT00141713
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Etanercept
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

NCT02946008
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy, Radical Prostatectomy
Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 13, 2026, 9:02 PM EDT
Not yet recruiting Phase 1 Interventional

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07682649
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Other · Drug + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

NCT04754399
View directory record Official record
Conditions
Arthralgia, Breast Cancer
Interventions
Cannabidiol (CBD)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

NCT00405327
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions
Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
Biological · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

NCT02059213
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ibrance, Bicalutamide, Zoladex, Lupron Depot
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

NCT05764005
View directory record Official record
Conditions
Prostate Cancer
Interventions
web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

NCT00143845
View directory record Official record
Conditions
Multiple Myeloma, Lymphocytic Leukemia, Chronic, Lymphoma, Low-Grade
Interventions
Reduced intensity conditioning, Rapid immunosuppressive taper, Prophylactic donor leukocyte infusions
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Living Well With Lymphoma

NCT06047626
View directory record Official record
Conditions
Lymphoma
Interventions
Fatigue Reduction Diet, General Health Curriculum
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Genomics in Michigan Impacting Observation or Radiation

NCT02783950
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Prostate Cancer Classifier
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
13
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

NCT00585689
View directory record Official record
Conditions
Bladder Cancer
Interventions
ABI-007, Carboplatin, Gemcitabine, Radical Cystectomy
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

NCT06941324
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Best Practice, Communication Intervention, Discussion, Health Promotion and Education, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Active, not recruiting Phase 2 Interventional

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

NCT04748042
View directory record Official record
Conditions
Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
Interventions
Abiraterone, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib
Drug · Radiation · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT03416153
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Carboplatin, Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

NCT00115739
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Imatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 13, 2026, 9:02 PM EDT
Terminated Not applicable Interventional

Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program

NCT04616651
View directory record Official record
Conditions
Cancer
Interventions
Online Survey, Chatbot prototype, Open to Options (O2O) Program
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

NCT00189137
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
ifosfamide and doxorubicin vs gemcitabine and docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting Phase 1 Interventional

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

NCT07532525
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Pomalidomide
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

NCT00151047
View directory record Official record
Conditions
Prostate Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 13, 2026, 9:02 PM EDT
Recruiting No phase listed Observational

Localized Leiomyosarcoma Biomarker Protocol

NCT04925089
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Blood and Tissue collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 13, 2026, 9:02 PM EDT